BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Table 3 Univariate and multivariate Cox analysis for overall survival
CharacteristicsUnivariate analysis
Multivariate analysis
HR (95%CI)

P value
HR (95%CI)

P value
Gender (female vs male)1.551 (0.604-3.984)0.362
Age (< 65 vs ≥ 65 years)0.937 (0.428-2.054)0.871
Hepatitis B infection (no vs yes)0.910 (0.426-1.944)0.807
Hepatitis C infection (no vs yes)0.000 (0.000-inf)0.997
Diabetes (no vs yes)3.291 (1.362-7.952)0.0084.319 (0.783-23.801)0.093
Hypertension (no vs yes)1.267 (0.646-2.483)0.491
Smoking (no vs yes)1.042 (0.516-2.101)0.909
Drinking (no vs yes)1.120 (0.531-2.360)0.766
Tumor size (≤ 5 vs > 5 cm)1.626 (0.728-3.631)0.235
Child-Pugh class (A vs B + C)2.456 (1.127-5.352)0.0241.100 (0.349-53.465)0.871
ECOG PS (0 vs ≥ 1)1.002 (0.454-2.212)0.996
Portal vein invasion tumor (no vs yes)1.473 (0.688-3.153)0.319
CNLC (IIa + IIb vs IIIa + IIIb)1.347 (0.685-2.649)0.388
ALT (≤ 50 vs > 50 IU/L)2.044 (0.993-4.207)0.0522.221 (0.984-5.011)0.055
AST (≤ 40 vs > 40 IU/L)1.353 (0.656-2.793)0.413
ALB (< 35 vs ≥ 35 g/L)0.659 (0.313-1.389)0.273
TBIL (≤ 23 vs > 23 μmol/L)0.622 (0.238-1.622)0.331
AFP (< 400 vs ≥ 400 ng/mL)2.332 (1.140-4.769)0.0201.805 (0.743-4.383)0.192
INR (≤ 1.2 vs > 1.2)0.720 (0.098-5.294)0.747
First-line ICI therapy (no vs yes)1.891 (0.921-3.883)0.0832.159 (0.794-5.868)0.132
Initial daily dose of regorafenib (< 160 vs 160 mg)1.440 (0.594-3.491)0.419
Second-line PD-1 inhibitors therapy (no vs yes)0.505 (0.260-0.983)0.0440.502 (0.203-1.239)0.135


Write to the Help Desk